In a new job - June 9, 2022
BioInvent appoints Chief Business Officer
BioInvent International has announced the appointment of Sylvie Ryckebusch as Chief Business Officer (CBO). “Sylvie Ryckebusch has already made an important contribution to the development of BioInvent’s business, including the licensing deal with CASI Pharmaceuticals in 2020, the restructuring of a clinical development agreement with Cancer Research UK in 2021, and a supply and clinical […]
Clinical Trials - May 13, 2022
BioInvent’s BI-1206 to advance into expansion stage of Phase 1/2a study
BioInvent International has announced its novel anti-FcyRIIB antibody BI-1206 is progressing into the expansion phase of a Phase 1/2a trial for non-Hodgkin’s lymphoma (NHL), following a positive End-of-Phase 1 meeting with the US FDA. The Phase 1 data presented so far (December 2021) include early signs of efficacy in the form of three long-lasting complete […]
Biotech Business - May 5, 2022
BioInvent receives milestone payment
BioInvent International receives a milestone payment from Bayer/Hope Medicine following clinical progression of an out-licensed antibody. BioInvent receives EUR 500,000 following the enrollment of the first patient in a Phase 2 trial of HMI-115 for the treatment of endometriosis in pre-menopausal women. HMI-115 is an anti-prolactin receptor antibody discovered using BioInvent’s n-CoDeR phage display antibody […]
In a new job - February 20, 2022
BioInvent appoints new Chief Operating Officer
BioInvent International has announced the appointment of Marie Moores as Chief Operating Officer. Marie Moores joined the company on February 1, 2022, and she will be involved in all operational aspects including quality assurance as well as commercial strategy planning such as further developing the target product profiles for BioInvent’s drug candidates. Marie Moores Marie […]
Biotech Business - February 1, 2022
BioInvent granted Orphan Drug Designation by the FDA
BioInvent International has announces that its anti-FcyRllB antibody BI-1206 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma. BI-1206 previously received ODD from the FDA for the treatment of mantle cell lymphoma (MCL) in January 2019. BI-1206 […]
Clinical Trials - November 7, 2021
BioInvent shows further positive clinical data
BioInvent International has announced additional positive interim data from its novel anti-FcγRIIB antibody BI-1206. The data update comes from the company’s Phase 1/2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) treating patients with indolent relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The latest data will be published in a poster at […]
